ProCE Banner Activity

Management of Adverse Events Associated With New Therapies for AML: A Guide for the Healthcare Team

PDF
Download this PDF of expert recommendations on the optimal management of AEs experienced with recently approved targeted therapies in patients with advanced AML.

Released: August 02, 2018

Expiration: August 01, 2019

No longer available for credit.

Share

Faculty

Elizabeth S. Kaled

Elizabeth S. Kaled, NP

Advanced Practice Nurse
Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Deborah A. McCue

Deborah A. McCue, PharmD, BCOP

Manager, Clinical Pharmacy Services
Division of Pharmacy
The University of Texas MD Anderson Cancer Center
Houston, Texas

Farhad Ravandi

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Supporters

Agios Pharmaceuticals

Celgene

Faculty Disclosure

Primary Author

Elizabeth S. Kaled, NP

Advanced Practice Nurse
Leukemia Department
The University of Texas MD Anderson Cancer Center
Houston, Texas

Elizabeth Kaled, NP, has no real or apparent conflicts of interest to report.

Deborah A. McCue, PharmD, BCOP

Manager, Clinical Pharmacy Services
Division of Pharmacy
The University of Texas MD Anderson Cancer Center
Houston, Texas

Deborah A. McCue, PharmD, BCOP, has no real or apparent conflicts of interest to report.

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Dr. Ravandi has reported that he has received consulting fees from Amgen, Astellas, Macrogenix, and Orsenix, and funds for contracted research from Amgen, Bristol-Myers Squibb, Macrogenix, Orsenix, and Seattle Genetics.